Новые методы терапии в лечении кастрационнорезистентного рака предстательной железы


Цитировать

Полный текст

Открытый доступ Открытый доступ
Доступ закрыт Доступ предоставлен
Доступ закрыт Доступ платный или только для подписчиков

Аннотация

Рассматриваются проблемы лечения агрессивного кастрационнорезистентного рака предстательной железы (КРРПЖ), в терапии которого традиционно используется доцетаксел. В обзоре представлены клинические результаты применения нескольких новых препаратов, повышающих выживаемость пациентов с КРРПЖ. К их числу относятся полусинтетический таксан кабазитаксел, пероральный антагонист рецепторов андрогенов энзалутамид и стероидный ингибитор CYP17 абиратерон.

Полный текст

Доступ закрыт

Об авторах

Д. Г Соков

Онкологический клинический диспансер № 1 ФГУ МНИОИ им. П.А. Герцена Росмедтехнологии

к.м.н

Список литературы

  1. Huggins C., Hodges C.V. Studies on prostatic cancer. I. The effect of castration, of estrogen and androgen injection on serum phosphatases in metastatic carcinoma of the prostate. C.A. Cancer J. Clin. 1972; 22(4): 232-40.
  2. Tannock I.F., De Wit R., Berry W.R., et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N. Engl. J. Med. 2004; 351(15): 1502-12.
  3. Scher H.I., Jia X., Chi K., et al. Randomized, open-label phase III trial of docetaxel plus highdose calcitriol versus docetaxel plus prednisone for patients with castration-resistant prostate cancer. J. Clin. Oncol. 2011; 29(16): 2191-98.
  4. Miles D.W., Chan A., Dirix L.Y., et al. Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. J. Clin. Oncol. 2010; 28(20): 3239-47.
  5. Quinn D.I., Tangen C.M., Hussain M., et al. SWOG S0421: phase III study of docetaxel (D) and atrasentan (A) versus docetaxel and placebo (P) for men with advanced castrate resistant prostate cancer (CRPC). J. Clin. Oncol. 2012; 30(suppl): abstr. 4511.
  6. De Bono J.S., Oudard S., Ozguroglu M., et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet. 2010; 376(9747): 1147-54.
  7. De Bono J.S., Logothetis C.J., Molina A., et al. Abiraterone and increased survival in metastatic prostate cancer. N. Engl. J. Med. 2011; 364: 1995-2005.
  8. Scher H.I., Fizazi K., Saad F., et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N. Engl. J. Med. 2012; 367: 1187-97.
  9. Kantoff P.W., Higano C.S., Shore N.D., et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N. Engl. J. Med. 2010; 363(5): 411-22.
  10. Sartor A.O., Heinrich D., O'Sullivan J.M., et al. Radium-223 chloride (Ra-223) impact on skeletal-relatedevents (SREs) and ECOG performance status (PS) in patients with castration-resistant prostate cancer (CRPC) with bone metastases: interim results of a phase III trial (ALSYMPCA). J. Clin. Oncol. 2012; 30(suppl): abstr. 4551.
  11. Galletti E., Magnani M., Renzulli M.L., Botta M. Paclitaxel and docetaxel resistance: molecular mechanisms and development of new generation taxanes. Chem. Med. Chem. 2007; 2(7): 920-42.
  12. Bissery M.C., Bouchard H., Riou J.F., et al. Preclinical evaluation of TXD258, a new taxoid. Proceedings of the 91st American Association for Cancer Research; 2000; San Francisco, Calif, USA.
  13. Gelmon K.A., Latreille J., Tolcher A., et al. Phase I dose-finding study of a new taxane, RPR 109881A, administered as a one-hour intravenous infusion days 1 and 8 to patients with advanced solid tumors. J. Clin. Oncol. 2000; 18(24): 4098-108.
  14. Mita A.C., Denis L.J., Rowinsky E.K., et al. Phase I and pharmacokinetic study of XRP6258 (RPR 116258A), a novel taxane, administered as a 1-hour infusion every 3 weeks in patients with advanced solid tumors. Clin. Cancer Res. 2009; 15(2): 723-30.
  15. Paller C.J., Antonarakis E.S. Cabazitaxel: a novel second-line treatment for metastatic castration-resistant prostate cancer. Drug Des Devel Ther. 2011; (5): 117-24.
  16. Dieras V., Limentani S., Romieu G., et al. Phase II multicenter study of larotaxel (XRP9881), a novel taxoid, in patients with metastatic breast cancer who previously received taxane-based therapy. Ann. Oncol. 2008; 19(7): 1255-60.
  17. Tilley W.D., Lim-Tio S.S., Horsfall D.J., et al. Detection of discrete androgen receptor epitopes in prostate cancer by immunostaining: measurement by color video image analysis. Cancer Res. 1994; 54(15): 4096-102.
  18. Visakorpi T., Hyytinen E., Koivisto P., et al. In vivo amplification of the androgen receptor gene and progression of human prostate cancer. Nat. Genet. 1995; 9(4): 401-06.
  19. Tran C., Ouk S., Clegg N.J., et al. Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science. 2009; 324(5928): 787-90.
  20. Cheng H., Snoek R., Ghaidi F., Cox M.E., Rennie P.S. Short hairpin RNA knockdown of the androgen receptor attenuates ligand-independent activation and delays tumor progression. Cancer Res. 2006; 66(21): 10613-20.
  21. Chen C.D., Welsbie D.S., Tran C., et al. Molecular determinants of resistance to antiandrogen therapy. Nat. Med. 2004; 10(1): 33-9.
  22. Culig Z., Comuzzi B., Steiner H., Bartsch G., Hobisch A. Expression and function of androgen receptor coactivators in prostate cancer. J. Steroid Biochem. Mol. Biol. 2004; 92(4): 265-71.
  23. Giri D., Ozen M., Ittmann M. Interleukin-6 is an autocrine growth factor in human prostate cancer. Am. J. Pathol. 2001; 159(6): 2159-65.
  24. Locke J.A., Guns E.S., Lubik A.A., et al. Androgen Levels increase by intratumoral de novo steroidogenesis during progression of castration-resistant prostate cancer. Cancer Res. 2008; 68(15): 6407-15.
  25. Scher H.H., Anand A., Rathkopf D., et al. Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study. Lancet. 2010; 375(9724): 1437-46.
  26. Scher H.H., Fizazi K., Saad F., et al. Effect of MDV3100, an androgen receptor signaling inhibitor (ARSI), on overall survival in patients with prostate cancer postdocetaxel: results from the phase III AFFIRM study. J. Clin. Oncol. 2012; 30(suppl 5): abstr. LBA1.
  27. Foster W.R., Car B.D., Shi H., et al. Drug safety is a barrier to the discovery and development of new androgen receptor antagonists. Prostate. 2011; 71(5): 480-88.
  28. Clegg N.J., Wongvipat J., Joseph J.D., et al. ARN-509: a novel antiandrogen for prostate cancer treatment. Cancer Res. 2012; 72: 1494-503.
  29. Auchus R.J. The genetics, pathophysiology, and management of human deficiencies of P450c17. Endocrinol. Metab. Clin. North Am. 2001; 30(1): 101-19.
  30. Potter G.A., Elaine Barrie S., Jarman M., Rowlands M.G. Novel steroidal inhibitors of human cytochrome P45017a (17a-hydroxylase-C17,20-lyase): potential agents for the treatment of prostatic cancer. J. Med. Chem. 1995; 38(13): 2463-71.
  31. Barrie S.E., Potter G.A., Goddard P.M., et al. Pharmacology of novel steroidal inhibitors of cytochrome p450(17α) (17α-hydroxylase/C17-20 lyase). J. Steroid Biochem. Mol. Biol. 1994; 50(5-6): 267-73.
  32. Chan F.C.Y., Potter G.A., Barrie S.E., et al. 3and 4-pyridylalkyl adamantanecarboxylates: inhibitors of human cytochrome P450(17α) ( 17α-hydroxylase/C17,20-lyase). Potential nonsteroidal agents for the treatment of prostatic cancer. J. Med. Chem. 1996; 39(17): 3319-23.
  33. Ryan C.J., Smith M.R., Fong L., et al. Phase I clinical trial of the CYP17 inhibitor abiraterone acetate demonstrating clinical activity in patients with castration-resistant prostate cancer who received prior ketoconazole therapy. J. Clin. Oncol. 2010; 28(9): 1481-88.
  34. Tolcher A.W., Chi K.N., Shore N.D., et al. Effect of abiraterone acetate plus prednisone on the QT interval in patients with metastatic castrationresistant prostate cancer. Cancer Chemother. Pharmacol. 2012; 70: 305-13.
  35. Fizazi K., Carducci M., Smith M., et al. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, doubleblind study. Lancet. 2011; 377(9768): 813-22.
  36. Jarman M., Elaine Barrie S., Liera J.M. The 16,17-double bond is needed for irreversible inhibition of human cytochrome P45017a by abiraterone ( 17-(3-Pyridyl)androsta-5,16-dien-3β-ol) and related steroidal inhibitors. J. Med. Chem. 1998; 41(27): 5375-81.
  37. Hara T., Kouno J., Kaku T., et al. Effect of a novel 17,20-lyase inhibitor, orteronel (TAK-700), on androgen synthesis in male rats. J. Steroid Biochem. Mol. Biol. 2013; 134: 80-91.
  38. Agus D.B., Stadler W., Shevrin D.H., et al. Safety, efficacy, and pharmacodynamics of the investigational agent TAK-700 in metastatic castration-resistant prostate cancer (mCRPC): updated data from a phase I/II study. J. Clin. Oncol. 2011; 29(suppl): abstr. 4531.

Дополнительные файлы

Доп. файлы
Действие
1. JATS XML
Скачать

© ООО «Бионика Медиа», 2014

Данный сайт использует cookie-файлы

Продолжая использовать наш сайт, вы даете согласие на обработку файлов cookie, которые обеспечивают правильную работу сайта.

О куки-файлах